Korean J Schizophr Res.  2020 Oct;23(2):71-77. 10.16946/kjsr.2020.23.2.71.

Association Study between Serotonin 1A Receptor Gene rs6295 Polymorphism and Tardive Dyskinesia in Patients with Schizophrenia

• Lee YJ
• Namgoong Y
• Cho A
• Lee HJ

• KMID: 2508355
• DOI: http://doi.org/10.16946/kjsr.2020.23.2.71

Abstract

OBJECTIVES
Tardive dyskinesia (TD) is a movement disorder that is characterized by hyperkinetic movements. Previous studies have suggested that the serotonergic systems are correlated with TD vulnerability. In this study, the association between a single-nucleotide polymorphism (SNP) of the serotonin 1A receptor gene (HTR1A) rs6295 and TD was investigated.
METHODS
We investigated whether HTR1A rs6295 SNP is associated with antipsychotic-induced TD in 280 Korean patients with schizophrenia. Patients with schizophrenia having TD (n=105) and those without TD (n=175) were matched for their antipsychotic exposures and other relevant variables. The HTR1A rs6295 SNP was analyzed using polymerase chain reaction (PCR)-based methods.
RESULTS
There was no significant difference in the distribution of genotypic (χ²=2.70, p=0.26) and allelic (χ²=1.87, p=0.17) frequencies between the patient groups with TD and without TD. There was no significant difference in total abnormal involuntary movement scale score (F=0.39, p=0.68) among the genotype group either.
CONCLUSION
Although there were no differences in genotypic and allelic frequency between patient groups with and without TD, further studies on association of TD with other SNPs of HTRA1 are needed to understand the pathophysiological mechanism of TD.

Keyword

HTR1A; rs6295; Schizophrenia; Single-nucleotide polymorphism (SNP); Tardive dyskinesia; 단일염기다형성; 조현병; 지연성 운동이상; HTR1A; rs6295

Reference

1. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010; 71:463–474.

2. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018; 32:135–147.

3. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res. 1991; 4:109–120.

4. Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019; 59:151–154.

5. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand. 2001; 104:375–379.

6. Weinhold P, Wegner JT, Kane JM. Familial occurrence of tardive dyskinesia. J Clin Psychiatry. 1981; 42:165–166.

7. Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Psychopharmacol Bull. 1978; 14:79–81.

8. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol. 2000; 61:525–541.

9. Haleem DJ, Khan NH. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:645–651.

10. Naidu PS, Kulkarni SK. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol. 2001; 428:81–86.

11. Mason SL, Reynolds GP. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol. 1992; 221:397–398.

12. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology. 1996; 35:119–121.

13. Prinssen EP, Kleven MS, Koek W. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl). 1999; 144:20–29.

14. Le Francois B, Czesak M, Steubl D, Albert PR. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology. 2008; 55:977–985.

15. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004; 22:246–260.

16. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996; 708:209–214.

17. Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, et al. The--1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol. 2008; 22:904–909.

18. Kishi T, Okochi T, Tsunoka T, Okumura T, Kitajima T, Kawashima K, et al. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. Psychiatry Res. 2011; 185:20–26.

19. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics. 2009; 19:91–94.

20. Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, UmeneNakano W, et al. The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2013; 263:105–118.

21. Huang YY, Battistuzzi C, Oquendo MA, Harkavy-Friedman J, Greenhill L, Zalsman G, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol. 2004; 7:441–451.

22. Yen JY, Tu HP, Chen CS, Yen CF, Long CY, Ko CH. The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder. Eur Arch Psychiatry Clin Neurosci. 2014; 264:729–739.

23. Dhingra V, Magnay JL, O’Brien PM, Chapman G, Fryer AA, Ismail KM. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol. 2007; 110:788–792.

24. Donaldson ZR, le Francois B, Santos TL, Almli LM, Boldrini M, Champagne FA, et al. The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription. Transl Psychiatry. 2016; 6:e746.

25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, version IV, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association;2000. p. 75.

26. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982; 39:486–487.

27. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull. 1988; 24:781–783.

28. Park YM, Kang SG, Choi JE, Kim YK, Kim SH, Park JY, et al. No Evidence for an association between dopamine D2 receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig. 2011; 8:49–54.

29. Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia. Psychiatry Investig. 2009; 6:108–111.

30. Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology. 2007; 55:47–51.

31. Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol. 2007; 22:501–504.

32. Kim IS, Yoon HK, Kang SG, Park YM, Kim YK, Kim SH, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients. Psychiatry Investig. 2012; 9:191–194.

33. Kang SG, Choi JE, Park YM, Lee HJ, Han C, Kim YK, et al. Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology. 2008; 57:22–25.

34. Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:1844–1847.

35. Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:1545–1548.

36. Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol. 2009; 24:55–60.

37. Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46:207–213.

38. Son WY, Lee HJ, Yoon HK, Kang SG, Park YM, Yang HJ, et al. Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia. Nord J Psychiatry. 2014; 68:123–128.

39. Johnson SK, Wagner GC, Fischer H. Neurochemical and motor effects of high dose haloperidol treatment: exacerbation by tryptophan supplementation. Proc Soc Exp Biol Med. 1992; 200:571–575.

40. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, et al. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit. 2002; 8:BR354–361.

41. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Involvement of serotonin in clinical features of Parkinson’s disease and complications of L-DOPA therapy. Adv Neurol. 1996; 69:545–550.

42. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev. 1991; 43:587–604.

43. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 2001; 6:225–229.

44. Marazziti D, Rossi A, Palego L, Giannaccini G, Naccarato A, Lucacchini A, et al. [3H]ketanserin binding in human brain postmortem. Neurochem Res. 1997; 22:753–757.

45. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 1995; 56:2209–2222.

46. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012; 38:167–177.

47. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008; 28:203–209.

48. Mombereau C, Arnt J, Mork A. Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats. Pharmacol Biochem Behav. 2017; 153:141–146.

49. Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol. 2002; 453:217–221.

50. Samad N, Khan A, Perveen T, Haider S, Abdul Haleem M, Haleem DJ. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia. Acta Neurobiol Exp (Wars). 2007; 67:389–397.

51. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev. 1992; 72:165–229.

52. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther. 1990; 253:803–811.

53. Haleem DJ, Shireen E, Haleem MA. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28:1323–1329.